Counter-terrorism at FDA Andrea Meyerhoff MD Director, Office of Counter-terrorism US Food and Drug Administration.

Slides:



Advertisements
Similar presentations
Public Health and Healthcare Issues. Public Health and Healthcare.
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
The Laboratory Response Network
1 GOOD MORNING! BONJOUR! GOEDEMORGEN!. 2 An Introduction to certain aspects of the US FDA Murray M. Lumpkin, MD Deputy Commissioner International Programs.
Ready or Not? Protecting the Public’s Health from Diseases, Disasters, and Bioterrorism Jeffrey Levi, PhD Congressional Briefing February 3, 2012.
Christa-Marie Singleton, MD, MPH Associate Director for Science
1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis Anti-Infectives Advisory Committee Meeting July 28, 2000 Andrea Meyerhoff.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
History of FDA and Related Regulatory Agencies
North Carolina’s Role in Preparedness. Objectives How you fit into the LRN Describe critical aspects of lab preparedness, surveillance and reporting,
Introduction to Regulation
Becker Grand Rounds: Wally Pellerite June 30, 2011.
FDA Perspective Sally Loewke, M.D. Acting Division Director
The Laboratory Response Network
1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis.
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
RADM Ali S. Khan, MD, MPH Director, Office of Public Health Preparedness and Response Bridging the Gaps: Public Health and Radiation Emergency Preparedness.
Enrollment of Women and Racial Minorities in Clinical Trials for Diabetes Medications Ellen Pinnow 1, Pellavi Sharma 1, Ameeta Parekh 1, Kimberly Thomas.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Special Topics in IND Regulation
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Bioterrorism MLAB 2434: Microiology Keri Brophy-Martinez.
Introduction to US Health Care
Food Supply Defense Plan: Lessons from Oregon Public Health
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
FDA, PDUFA AND MEDICAL INNOVATION Spring WHAT IS THE FOOD AND DRUG ADMINISTRATION (FDA)? The FDA is an agency within the U.S. Department of Health.
Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
“History is a set of lies agreed upon.” Napoleon Bonaparte.
Food and Drug Administration & Outbreaks
Public Health Issues Associated with Biological and Chemical Terrorism Scott Lillibridge, MD Director Bioterrorism Preparedness and Response Activity National.
Celeste F. Bové, M.A., CCC-A Senior Science Policy Analyst Office of Science Coordination & Communication Food and Drug Administration FDA Participation.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule.
The Integrated National Biodefense Portfolio Initiative “One-Portfolio” Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF) May 6, 2009.
November 6, 2003 FDA Science Board Center for Drugs: CT Medical Countermeasures Dianne Murphy, M.D. Director Office of Counterterrorism & Pediatric Drug.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
1 Pharmacists’ Roles in Emergency Preparedness CDR Louis Flowers LT Evan Wearne.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.
Veterinary Laboratory Investigation and Response Network Renate Reimschuessel 1, Sarah Nemser 1, Andriy Tkachenko 1, Olgica Ceric 1, Jake Guag 1, David.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
USDA HHS/ FDA Treasury Commerce The Need for a Single Food Safety Agency Caroline Smith DeWaal Center for Science in the Public Interest September 2002.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.
My Experiences as an FDA Statistician
נמטוציטים משושנת ים Eli. S Lec. No.2.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Case Studies in Big Data and Analysis
Clinical Trials — A Closer Look
FDA Perspective on Cardiovascular Device Development
American Society for Quality Region 5 Quality Conference
Biological agents that might be used as weapons of Bioterrorism
North Carolina’s Role in Preparedness
Overview of FDA Food Inspections
Food Supply Defense Plan: Lessons from Oregon Public Health
Visualization Using Open-Source Tools: some FDA perspectives
Patient Involvement in the Development and Safe Use of
Allen Chan U.S. Government Accountability Office October 2, 2018
North Carolina’s Role in Preparedness A Brief Overview
Care of Research Animals
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Counter-terrorism at FDA Andrea Meyerhoff MD Director, Office of Counter-terrorism US Food and Drug Administration

Overview FDA mandate in counter-terrorism (CT) CT Strategic Plan Organization of CT activities Scientific issues in CT

FDA mandate: counter-terrorism Law Enforcement –To prevent, investigate and respond to tampering with food and animal feed, blood, radiation-emitting instruments, drugs, vaccines, medical devices Public Health –To facilitate the availability of safe and effective medical countermeasures-drugs, vaccines, medical devices -for individuals exposed to a biological, chemical, or nuclear agent

FDA mandate: counter-terrorism Civilian –generally operate in areas of lower risk –special populations, e.g., children, elderly –public health actions in counter-terrorism likely to follow sentinel event Military –potential to operate in areas of highest risk –generally healthy adults –public health actions may precede event

FDA Counter-terrorism Strategic Plan

Pre September 11 CT Budget $8.2 million Bioterrorism: Adequate supply of drugs, vaccines, biologicals CDER & CBER FDA’s CT activities pre/post September 11, 2001 Post September 11 CT Budget > $159 million Counter-terrorism: Full range of FDA products Total agency involvement

Counterterrorism Strategic Plan Goal 1: Safety and security of regulated products (deterrence, detection, investigation and interdiction) Goal 2: Medical countermeasures Goal 3: Emergency preparedness and response Goal 4: Radiation safety

Goal 1: Deterrence, detection, investigation and interdiction: safety and security of FDA regulated products

Goal 2: Medical countermeasures

Goal 3: Emergency preparedness and response

Goal 4: Radiation safety

Organization of FDA Counter- terrorism activities

Office of the Commissioner: Office of Crisis Management Office of Security Operations, Policy and Planning Office of Emergency Operations Office of Counter-terrorism

Organization from the outside: CT queries to FDA Sources –Industry, academic investigator, foreign government, other federal agency, state/local governments, concerned private citizen Portal of entry FDA –Office of CT, Office of the Commissioner Queries –FDA jurisdiction? –Funding? –Where/What in FDA?

Organization from the inside: CT Steering Committee 5 Centers –CFSAN (foods and cosmetics) –CVM (veterinary medicine) –CDER (drugs) –CBER (vaccines and other biologics) –CDRH (medical devices and radiation- emitting instruments) Office of Regulatory Affairs (field operations) NCTR (toxicology labs) Press, congressional, legal, international affairs, budget, planning and evaluation

FDA scientific issues in Counter-terrorism New standards development building on regulatory precedent

FDA: Scientific issues in CT Medical countermeasures –Drugs and biologics –Diagnostic devices Food security Radiation safety

OrganismDisease Variola majorSmallpox Bacillus anthracisAnthrax Yersinia pestisPlague C. botulinum toxinBotulism Francisella tularensisTularemia Filo-/ArenavirusesHem fever Biological Agents: Category A US CDC, 1999

Medical countermeasures: drugs and biologics Rare diseases: indications with little regulatory precedent Efficacy endpoints for animal models Availability of non-human primates Availability of laboratory space

Medical countermeasures: ciprofloxacin for anthrax Accelerated approval –Surrogate= human serum levels Cipro –Reached or exceeded monkey serum levels –Consistently higher than MIC B. anthracis –Associated with improved survival in animals exposed to aerosolized B. anthracis spores compared with those animals receiving placebo –Database of human pathology permitting direct comparison with animal model (Sverdlovsk, 1979) –Database of US industrial exposure

Ciprofloxacin Trough Concentrations - All

Challenge (from Friedlander et al 1993) Survival TOC End of treatment

Ciprofloxacin safety Approved 1987, used > 250 million >1000 patients > 60 days (clinical trials) Compared with patients Cipro® short course and active controls GI most common, generally similar rates across all 3 groups Abdominal pain (3.5%), rash (3.9%) more common > 60 days Cipro® group No previously unidentified AEs

Medical countermeasures: diagnostic devices New range of biological agents to assay First step in identifying an outbreak or intentional release of biologic agent Public health, infrastructure, economic consequences linked to performance of assays Need for sensitivity and specificity standards Need to validate the assays

Food security: test methods development Detection of biological agents in various food matrices Questions –Survival of pathogen in matrix? –Can pathogen cause human disease following oral ingestion? –Relevant inoculum causing clinical disease?

Radiation safety Decades of experience Expertise in –radiological public health –population dosimetry studies from medical x-ray –emergency response Science credentials and on-the-job training Need for inventory in training and expertise

Conclusion: FDA counter- terrorism programs FDA mandate –Regulated products meet a standard of purity, safety and effectiveness and are available Public health emergency –Rapid availability of regulated products for large- scale use FDA role in counter-terrorism –Availability of pure, safe and effective products consistent with the legal responsibilities of regulatory agency